Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs
Citations Over TimeTop 10% of 2015 papers
Abstract
A convenient synthesis of imatinib, a potent inhibitor of ABL1 kinase and widely prescribed drug for the treatment of a variety of leukemias, was devised and applied to the construction of a series of novel imatinib analogues featuring a number of non-aromatic structural motifs in place of the parent molecule's phenyl moiety. These analogues were subsequently evaluated for their biopharmaceutical properties (e.g., ABL1 kinase inhibitory activity, cytotoxicity). The bicyclo[1.1.1]pentane- and cubane-containing analogues were found to possess higher themodynamic solubility, whereas cubane- and cyclohexyl-containing analogues exhibited the highest inhibitory activity against ABL1 kinase and the most potent cytotoxicity values against cancer cell lines K562 and SUP-B15. Molecular modeling was employed to rationalize the weak activity of the compounds against ABL1 kinase, and it is likely that the observed cytotoxicity of these agents arises through off-target effects.
Related Papers
- → Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia(2007)27 cited
- → Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case report(2004)15 cited
- → Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country(2010)10 cited
- → Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinib(2006)
- Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate(2007)